Trial Profile

A Randomized, Multicenter, Double-Blind, Superiority Study of Dotinurad (4 mg) and Febuxostat (40 mg) for the Treatment of Subjects With Gout

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 01 Aug 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dotinurad (Primary) ; Febuxostat
Indications Gout
Focus Registrational; Therapeutic Use
Sponsors Eisai Co Ltd

Most Recent Events

14 Jul 2025 Results published in the Media Release
14 Jul 2025 Primary endpoint has been met. (Percentage of Participants Who Achieve Serum Uric Acid (SUA) Level 6.0 mg/dL at Week 24)
11 Dec 2024 Results presented in the Eisai Co Ltd media release Media Release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com